Asklepios BioPharmaceutical (AskBio) is a frontrunner in the gene therapy sector, focused on the end-to-end development of molecular medicines. By operating as an independently managed subsidiary of Bayer AG, AskBio combines the agility and innovative spirit of a biotech pioneer with the resources of a global healthcare leader. Their work spans critical therapeutic areas, including the central nervous system, cardiovascular health, and rare metabolic conditions.
The company is distinguished by its proprietary technology stack, most notably the Pro10 manufacturing platform, which addresses one of the industry's biggest challenges: scalable production. With a deep commitment to scientific integrity and patient impact, AskBio continues to expand its reach, offering professionals the chance to work on groundbreaking therapies that have the potential to rewrite the standard of care for patients worldwide.